Image

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Exploring new treatments for certain breast cancer patients.

Recruiting
18 years and older
All
Phase 3

This study is for people with a type of breast cancer called *triple-negative breast cancer* (TNBC). TNBC is a form of cancer that does not have three common traits (receptors) usually found in breast cancer. The study compares two treatments: one using a combination of two drugs called sacituzumab tirumotecan (sac-TMT) and pembrolizumab, and the other is a treatment of the doctor's choice.

This study is for those who did not achieve a *pathological complete response* (pCR), meaning the cancer was not completely gone after initial treatment and surgery. The main goal is to see if the combination of sac-TMT and pembrolizumab helps patients live longer without the cancer coming back, compared to other treatments.

  • Participants must have had prior specific treatments and surgery.
  • The study involves random assignment to one of the treatment groups within 12 weeks after surgery.
  • Participants must not have certain medical conditions or be taking certain medications.

This study may offer a new treatment option, but it's important to consider potential risks and eligibility criteria before joining.

Study details
    Triple-Negative Breast Cancer

NCT06393374

Merck Sharp & Dohme LLC

8 March 2025

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

  Other languages supported:

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.